Avita Medical (RCEL) to Release Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Avita Medical to post earnings of ($0.38) per share and revenue of $29.39 million for the quarter. Avita Medical has set its FY 2025 guidance at EPS.Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12). Avita Medical had a negative net margin of 68.87% and a negative return on equity of 632.62%. The firm had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $34.27 million. On average, analysts expect Avita Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avita Medical Price Performance

NASDAQ:RCEL opened at $3.78 on Tuesday. The firm’s fifty day moving average price is $4.79 and its 200 day moving average price is $5.76. Avita Medical has a 1-year low of $3.60 and a 1-year high of $14.16. The firm has a market cap of $100.62 million, a price-to-earnings ratio of -1.92 and a beta of 1.58.

Analysts Set New Price Targets

RCEL has been the topic of a number of analyst reports. BTIG Research lowered shares of Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 price objective on the stock. in a research report on Friday, August 8th. Zacks Research lowered shares of Avita Medical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 21st. Lake Street Capital lowered shares of Avita Medical from a “buy” rating to a “hold” rating and lowered their price objective for the company from $8.00 to $4.00 in a research report on Friday, October 17th. Wall Street Zen lowered shares of Avita Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avita Medical in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $10.80.

Insider Activity at Avita Medical

In related news, Director Robert Mcnamara bought 10,000 shares of the firm’s stock in a transaction on Thursday, August 28th. The shares were bought at an average cost of $4.50 per share, for a total transaction of $45,000.00. Following the transaction, the director owned 86,771 shares of the company’s stock, valued at approximately $390,469.50. This trade represents a 13.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have acquired 24,000 shares of company stock worth $113,660. 2.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Avita Medical

Institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company purchased a new stake in shares of Avita Medical during the 2nd quarter worth $58,000. Curi Capital LLC acquired a new position in shares of Avita Medical during the 2nd quarter worth $100,000. Strs Ohio acquired a new position in shares of Avita Medical during the 1st quarter worth $116,000. XTX Topco Ltd acquired a new position in shares of Avita Medical during the 2nd quarter worth $153,000. Finally, Gabelli Funds LLC acquired a new position in shares of Avita Medical during the 2nd quarter worth $185,000. 27.66% of the stock is currently owned by hedge funds and other institutional investors.

About Avita Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.